Bristol Myers Squibb
Tracked across 7 events · 77 articles · First seen Feb 01, 2026 · Last active Apr 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Bristol Myers Squibb has initiated a Phase 1 clinical study for BMS-986506, a CELMoD agent, for clear cell renal cell carcinoma. This marks a significant advancement in its strategic protein degradation collaboration with Evotec.
Mar 19, 2026 · 9 articles
Business
Bristol Myers Squibb is a key player in the CAR T cell market, actively focusing on innovation, strategic collaborations, and pipeline expansion to enhance efficacy, safety, and accessibility of next-generation therapies.
Feb 16, 2026 · 7 articles
Regulatory
Bristol Myers Squibb, a multinational innovator, may experience increased patient numbers for its therapies in India as a result of the customs duty exemption on cancer drugs.
Feb 01, 2026 · 9 articles
Business
Bristol Myers Squibb had an existing collaboration with Tubulis, which will now be impacted by Tubulis' acquisition by Gilead Sciences. The nature of this impact is not fully detailed but suggests a shift in the competitive landscape for ADC development.
Apr 07, 2026 · 8 articles
Regulatory
Bristol Myers Squibb has previously struck deals with the Donald Trump administration to avoid new levies, indicating a willingness to negotiate on drug prices.
Apr 02, 2026 · 27 articles
+ 2 more events
View on Dashboard
50
Tubulis partnered with Bristol Myers SquibbGilead Sciences Acquires...
NEWSDESK
Track Bristol Myers Squibb live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard